Understand the source comparison
Adamax Safe Side Effects: Comparison Across Nootropic Peptides
Adamax (Semax) BDNF upregulation + MAO-B inhibition + melanocortin activation 12–18% (typically resolves within 5–10 days) 8–15% (higher in COMT Met/Met carriers) 6–10% in susceptible individuals (transient BP elevation 8–15 mmHg) Effective neuroprotective wit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Adamax (Semax)
- BDNF upregulation + MAO-B inhibition + melanocortin activation
- 12–18% (typically resolves within 5–10 days)
- 8–15% (higher in COMT Met/Met carriers)
- 6–10% in susceptible individuals (transient BP elevation 8–15 mmHg)
- Effective neuroprotective with predictable risk profile. Pre-screening for cardiovascular and genetic factors significantly reduces adverse event probability
- Selank
- Anxiolytic via GABA modulation + enkephalin metabolism
- 2–4% (rare, typically mild)
- <1% (compound is anxiolytic, not anxiogenic)
- <2% (minimal sympathetic activation)
- Lower side effect burden than Semax but weaker cognitive enhancement effects. Preferred for anxiety-prone individuals
- Cerebrolysin
- Neurotrophic factor delivery (BDNF, NGF, CNTF)
- 8–12% (injection-site related in some cases)
- 3–6%
- 4–7% (rare reports of transient hypertension)
- Comparable neuroprotective efficacy to Semax with slightly lower neuropsychiatric side effects but requires intramuscular administration
- Dihexa
- BDNF receptor (TrkB) agonist
- 5–9%
- 6–10% (dose-dependent, appears at >5mg daily)
- 3–5%
- Potent cognitive enhancer with narrower therapeutic window than Semax. Small dose increases produce disproportionate side effect escalation
- P21 (Cerebrolysin fragment)
- CNTF pathway activation
- <5%
- <3%
- <2%
- Well-tolerated but limited human data compared to Semax. Safety profile appears favorable but efficacy benchmarks less established